I hovedundersøgelsen fik 21 (49%) af de 43 patienter, der fik Soliris, stabiliseret deres hæmoglobinprocent, og de behøvede i det store hele ikke transfusion af røde blodlegemer.
In the main study, 21 (49%) of the 43 patients receiving Soliris had stable haemoglobin levels, and, on average, they did not need any transfusions of red blood cells.